Objective To analyze the effects of bivalirudin combined with percutaneous coronary intervention（PCI） on myocardial perfusion

serum inflammatory factors and the risk of major adverse cardiovascular events（MACE） in patients with acute myocardial infarction（AMI）. Methods Eighty-four patients with AMI admitted in our hospital from October 2018 to October 2020 were selected as the research objects

all of them were treated with PCI

and they were randomly divided into study group and control group

42 cases in each group. The study group was treated with bivalirudin

and the control group was treated with heparin. The incidence of myocardial perfusion（TIMI grade 3

tmp3）

mace and cardiac function(left ventricular ejection fraction（LVEF）

left ventricular end systolic volume index（LVESVI）

left ventricular end diastolic volume index（LVEDVI） were compared between the two groups at 1 month after operation Left ventricular mass index（LVMI）

serum inflammatory factors（IL-6

IL-1β）

Oxidative stress [superoxide dismutase（SOD）

glutathione oxide dismutase（GSH PX）

malondialdehyde（MDA）]. Results There was no significant difference in the incidence of TIMI grade 3 between the two groups（92.86%

88.10%）（p>0.05）;The incidence of tmp3 in the study group was 80.95%

which was higher than 59.52% in the control group（p<0.05）;One month after operation

LVEF and LVESVI in the study group were higher than those in the control group

while LVMI and LVEDVI in the study group were lower than those in the control group（p<0.05）; One month after operation

the serum levels of IL-6 and IL-1 in the study group were significantly higher than those in the control group βCompared with the control group（p<0.05）; One month after operation

the levels of GSH PX and SOD in the study group were higher than those in the control group

and the level of MDA in the study group was lower than that in the control group（p<0.05）; The incidence of mace was 9.52% in the study group and 14.29% in the control group

there was no significant difference（p>0.05）. Conclusions Bivalirudin combined with PCI in the treatment of AMI can improve myocardial perfusion

enhance cardiac function

inhibit inflammatory response

regulate oxidative stress

and does not significantly increase the incidence of mace.